HIV Drug

Concert Starts HIV Trial, Bags $12M From Glaxo to Help Challenge Gilead’s Once-Daily Pill

Xconomy (Free subscription) | yesterday

Concert Pharmaceuticals, the Lexington, MA-based company that chemically modifies existing drugs to make them more attractive, has started human testing of an HIV medication which it hopes will help GlaxoSmithKline wrestle back market share it has been losing to Gilead Sciences, the world’s largest maker of HIV drugs. Concert will receive a $12 million payment from...

FDA Approves Labeling Update For Bristol-Myers’ HIV Drug - Update

Forex Analytics (Free subscription) | 11/07/2009

Bristol-Myers Squibb Co. (BMY) said one Thursday that the American authority had approved HIV-Droge Reyataz beschriftenupdate aiming at the monitoring of the drugs and food, to cover given in the long run the LOCKS of a study. Long-term data the LOCKS of a study showed that the treatment could oppress indeed Reyataz/r HIV-Virenlast in 96 [...] Post from: (c)Autor: Forex Analytics FDA Approves...

FDA Approves Labeling Update For Bristol-Myers’ HIV Drug - Update

Forex Analytics (Free subscription) | 11/07/2009

Bristol-Myers Squibb Co. (BMY) said one Thursday that the American authority had approved HIV-Droge Reyataz beschriftenupdate aiming at the monitoring of the drugs and food, to cover given in the long run the LOCKS of a study. Long-term data the LOCKS of a study showed that the treatment could oppress indeed Reyataz/r HIV-Virenlast in 96 [...] Post from: (c)Autor: Forex Analytics FDA Approves...

Gilead (GILD): New potential in 4-in-1 HIV drug

BloggingStocks (Free subscription) | 11/05/2009

Filed under: Newsletters , Gilead Sciences (GILD) , Stocks to Buy " Gilead Sciences (NASDAQ: GILD ) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe . The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing...

HIV drug study needs volunteers with dark hair

San Fransisco Chronicle (Free subscription) | 11/05/2009

Wanted: Dark-haired HIV-negative men and women to participate in a study designed to measure drug levels in hair. It's called the "Strand Study" and it's part of a larger effort by AIDS scientists to look at whether people who are HIV-negative can benefit...

Wanted: Dark-haired HIV-negative patients for study

ScrippsNews (Free subscription) | 11/05/2009

SAN FRANCISCO - Wanted: Dark-haired HIV-negative men and women to participate in a study designed to measure drug levels in hair. It's called the "Strand Study" and it's part of a larger effort by AIDS scientists to look at whether people who are HIV-negative can benefit from prophylactically taking anti-HIV drugs to reduce their chances of infection. | read more

• HIV drug study needs volunteers with dark hair - San Fransisco Chronicle

Research Assistant Post on anti-HIV drug testing

Phd Position in Biology (Free subscription) | 11/05/2009

... class in M.Sc. / with one year experience in research lab. Job Responsibilities To carry out anti-HIV drug testing of synthetic compounds. Date & Reporting Time for Interview 11 th -November 2009 Further Info on Research Assistant Vacancies on anti-HIV drug testing

Pharmaceutical Giants Create HIV Pool

Online Clinic News (Free subscription) | 11/05/2009

Two of the biggest pharmaceutical firms this week took the unusual move of pooling their HIV treatments. The new group has been named Viiv Healthcare and was formed by Pfizer and GlaxoSmithKline. Viiv will take over GSK’s collection of HIV medicines, which are becoming slightly outdated (one otf their biggest sellers Combivir is due to lose its patent in 3 years) and Pzifer’s new and largely...

GSK, Pfizer launch new HIV drug venture

Fiercebiotech (Free subscription) | 11/04/2009

The joint venture between GlaxoSmithKline and Pfizer , Viiv, has officially opened up for business as a powerhouse developer of new HIV therapies. But analysts are wondering if Viiv has more to do with getting the two pharma giants out of the controversial therapeutic area than with ramping up new drugs for the lethal virus. "By being 100 per cent dedicated to HIV, we will reach more patients...

Pfizer, GSK launch HIV drug company

The St Louis Business Journal (Free subscription) | 11/03/2009

Pharmaceutical giants Pfizer and GlaxoSmithKline have launched a joint venture to develop HIV treatments. (PFE) (GSK)

Gilead (GILD): 4-in-1 HIV drug

TheStockAdvisors.com (Free subscription) | 11/03/2009

The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead’s highest-grossing business. This segment has held up through the Great Recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion. The spike resulted from higher sales of Truvada and Atripla, two frequently prescribed HIV drugs....

5-Star Stocks Poised to Pop: Gilead Sciences

Fool.com (Free subscription) | yesterday

As long as [Gilead's] Atripla continues to be the lead choice of a single dose / single pill HIV treatment, it will gain market share as doctors put patients on this drug. Recent study showing that the company's anti-HIV drugs can be used in Africa without constant lab test monitoring of patients should boost significantly its opportunities in developing markets. Negatives can be competitors...

Research Scientist walk in Interview at NATIONAL AIDS RESEARCH INSTITUTE (NARI Pune)

Phd Position in Biology (Free subscription) | 11/07/2009

... Molecular Biology / Biotechnology / Life Science with experience in invitro / in vivo testing of drug and molecular biology. Job Responsibilities Detemination of anti- HIV activity using in vitro and in vivo methods, Determination of mechanism of action of drugs. Below 45 Research Scientist -I Essential Eligibility Qualification & Experience M.Sc. In Virology / Microbiology Molecular...